Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
biricodar + doxorubicin + vincristine
- Development stage
- Unknown
- Lead developer
- Vertex
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This is an investigational **combination regimen** of **biricodar (VX-710, Incel)**, a chemosensitizer and multidrug resistance inhibitor, with the established cytotoxic agents **doxorubicin** and **vincristine**. Biricodar acts by inhibiting efflux pumps such as **P-glycoprotein** (ABCB1) and **multidrug resistance-associated protein 1** (MRP1), restoring drug sensitivity to tumor cells that have become resistant to chemotherapy. Doxorubicin and vincristine are both classic chemotherapeutic agents: doxorubicin intercalates DNA and inhibits topoisomerase II, while vincristine inhibits microtubule formation, both leading to apoptosis of rapidly dividing cancer cells. The combination has been studied primarily in **chemotherapy-resistant solid tumors**, notably in **small cell lung cancer** and **soft tissue sarcoma**, seeking to overcome multidrug resistance and improve response rates[9][7][3][5].
- Brand names
- Incel + doxorubicin + vincristine
- Other names
- biricodar + doxorubicin + vincristine
02
Targets
ABCC1 (MRP1)ABCB1 (P-glycoprotein)TUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on biricodar + doxorubicin + vincristine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on biricodar + doxorubicin + vincristine.